Aaron Nesmith's two-year, $11M AAV deal earns a C+ CVI — a middling value proposition for a depth wing who's struggled to establish consistency in his sixth NBA season. At 26 years old, the 6-year veteran is posting 13.5 PPG and 4.1 RPG across 43 games, respectable counting stats that mask underlying efficiency concerns and questions about his reliability as a rotation piece. The $11M annual figure sits in awkward territory for small forwards — too expensive for a pure bench role but lacking the production to justify starter money, especially given his modest impact metrics and injury management issues that have drawn public criticism from coaching staff. Nesmith's career stage suggests this should be his peak earning window, but the mounting scrutiny around his performance on a struggling Pacers team and the "medicate" controversy have damaged his reputation as a dependable contributor. The relatively short two-year term provides some protection against downside risk, though the annual salary commitment feels steep for a player whose media framing consistently positions him as a low-profile role player with underlying reliability questions. With the Pacers clearly in evaluation mode after recent roster moves, Nesmith's contract represents a bet on complementary production that hasn't fully materialized.
Performance Analysis
C+
#32 of 119 Small Forwards
FCA+
Transaction History
No transactions found for this player.
News & Buzz
Live Discussion
Auto-moderated fan forum with 5-minute speaker turns
Aaron Nesmith earns a C+ Performance grade, reflecting league-average production for a small forward. This season, Aaron is putting up 13.5 points, 4.1 rebounds, and 1.9 assists per game across 330 games. Aaron's best relative area is PPG at 13.5, though it still falls below the small forward median of 15.0. The biggest area for growth is APG at 1.9 (small forward median: 4.0). Among 119 NBA small forwards graded this season, Aaron ranks 32nd.
Current Sentiment
B-
Positive
NegativeNeutralPositive
Aaron Nesmith's public perception sits at a B- heading into the back half of a difficult Pacers season, a modest but functional standing for a player who has never been mistaken for a marquee name. The dominant narrative around him is straightforward — he is valued as a reliable 3-and-D wing whose $11M AAV is aligned with the complementary role-player profile he occupies, and most observers who follow Indiana closely give him credit for his defensive intensity and consistent effort, with a recent Obi Toppin media availability specifically highlighting that work ethic as a talking point. That sentiment grade is actually a step above his C+ performance mark, a gap that speaks to the goodwill his blue-collar reputation generates even when the counting stats — 13.5 PPG, 4.1 RPG, and 1.9 APG across 43 games in the 2025-26 season — reflect a solid but unspectacular rotation starter rather than a difference-maker on a team mired at the bottom of the Eastern Conference. The most significant narrative disruptor is the uncomfortable report that the NBA sought to have Nesmith medicated, a headline that introduces a cloud of awkward scrutiny that has nothing to do with his on-court contributions and threatens to define his offseason story more than any box score ever could. The Pacers' recent roster activity — the Ivica Zubac trade and the additions of Jalen Slawson and Quenton Jackson — signals a franchise still actively tinkering rather than standing pat, which keeps the spotlight somewhat off Nesmith individually but also underscores that Indiana's front office is looking for answers in a season that has gone sideways. The bottom line is that Nesmith's narrative has actually trended upward over the last 30 days, driven more by the positive framing of his character and effort than by team success, but the medication controversy ensures this is a more complicated story than the straightforward 3-and-D praise he would otherwise receive.
